Some studies show that the inhibition of ALDOA, using GalNAc-siRNA or small molecule inhibitors, effectively suppresses cancer metabolism in HCC and PCa, suggesting that targeting ALDOA may be a promising target for treating cancer [61,64]. This evidence concerns the gene ALDOA and hepatocellular carcinoma.